Bruker Daltonics Introduces Powerful PTMscan(TM) on its High-Capacity Ion Trap PTM Discovery System(TM)Bruker Daltonics Introdu
13 March 2006 - 11:02PM
Business Wire
At Pittcon 2006, Bruker Daltonics today announces the release of a
powerful, novel PTMscan(TM) on its PTM Discovery System(TM). The
PTM Discovery System incorporates electron transfer dissociation
(ETD) in Bruker Daltonics' highly successful HCTultra(TM)
high-capacity ion trap mass spectrometer, the world's first and
only commercial system with fully integrated ETD capability. ETD
fragmentation breaks the peptide backbone non-ergodically and
preserves functionally important post-translational modifications
(PTMs), such as phosphorylation and glycosylation. The newly
introduced PTMscan can now detect PTMs by first screening for
specific neutral losses during collision-induced dissociation
(CID), and then triggering automatic, data-dependent ETD
experiments on the fly. A particularly important PTMscan, called
Phospho-PTMscan(TM) enables the automated detection and
localization of phosphorylations of peptides and small proteins.
Similar Glyco-PTMscan(TM) methods are supported as well. Dr.
Michael Schubert, Executive Vice President of Bruker Daltonics,
commented: "Last year, we introduced the world's first
high-capacity ion trap with ETD capability. This year, the PTMscan
methods further extend our customers' ability for automated,
intelligent phosphorylation and glycosylation characterization.
While similar PTM-analysis capabilities have been available on our
apex(R)-Qe FTMS systems, PTMscan now also enables this important
branch of proteomics on our robust, ultra-high sensitivity ion
traps. This further establishes Bruker Daltonics as the leader in
PTM and proteomics research by mass spectrometry." Pittcon 2006,
the 57th Pittsburgh Conference and Exposition on Analytical
Chemistry and Applied Spectroscopy, is being held from March 13-16
in Orlando, Florida in the Orange County Convention Center. Bruker
Daltonics will exhibit at booth #3155. ABOUT BRUKER BIOSCIENCES
(NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in
Billerica, Massachusetts, is the publicly traded parent company of
Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading
developer and provider of life science, materials research, and
industrial X-ray analysis tools. Bruker Daltonics is a leading
developer and provider of innovative life science tools based on
mass spectrometry. Bruker Daltonics also offers a broad line of
nuclear, biological and chemical (NBC) detection products for
defense and homeland security. For more information, please visit
www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-K, our most recent quarterly reports on Form 10-Q, and
our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024